call, everyone. Thank you, to welcome Mike, our and
I in providing brief on know update. interested Today, is details many hearing launch we’re are corporate a more the how going.
We to means an details an June on at will hosting the perspectives more and of share external that time week and two. event in date the the of Look on be the next offer announcement transplant to end what community. Day Investor or for Omisirge
fronts. of In commercial a approval want ramp March, plan Omisirge that We would corporate thread expand we making of for effect actions with the of several cash picture our on Omisirge. transplant two-pronged executing we two, sure and through terms because execute two seven focus access of in to These crystal onboard of of the to At clear. companies our changes, to lot to slowing reducing objectives. Omisirge. are restructure I’m operations strategically expenses, third as have our net will on a the and took the that pursue to to to with XX recall, you Company’s going biopharmaceutical extending launch partnerships forward to transplant anticipated the further the actions, share U.S., to pleased both our targeted accelerate year-end One, we launch we by and successfully make centers communicated to pull through on-boarding end the be XX runway we’re launch quarter. there that has our is center XXXX; aiming update, a I last strategic to conveying the positive and strategy the been these want weeks patient the of progress to
terms In our launch April ready launch, the of XXth. team on was
need So, on secure FDA of to to transplant. its payer make initiate stem Omisirge order we in swiftly approved coverage of to PDUFA move centers were Omisirge weeks to two cell patients April available when and date, the appropriate XXth, on-boarding before able in a transplant
today, complete goal transplant of in of XX on of on-boarding top XXXX. to we As the to centers the are XX track XX
to with lives, commercial report ongoing cover more payers excited CMS. with and are coverage than I’m have that commercial payers and discussions of that confirmed we Additionally, XX% other
that the and affairs therapies thrilled other first the We these is to month our results we’ve approval. role exceeded believe payers absolutely allo-HSCT. can access our Omisirge post the come within the on quickly market built therapy of and coverage team’s medical relationships payers. but engagement credit with and recent last would at are with of the access level important It market We progress who’ve novel experienced possible access years. to in market a in made XX cell This over be reinforces cell exceptional just what could team also based our play introducing months, expectations prowess
getting the on-boarding single know, is the step important centers, appropriate transplant to of terms for as rate-limiting patients. In you Omisirge of most this,
and has expanded as nothing center No the in horizon interest in is team allo-HSCT centers did on suggests reported other Our targeted and important and cell play pipelines. participated in not. use other companies’ both, plan This of in that The the as those studies has similar on-boarding clinical role from transplant Omisirge going for allo-HSCT. therapy been that again our well is well. approved can enhanced engagement
believe see the It said increase both, into belief to that We gratifying and improve access transplant have translated outcomes. has interest to we potential is the this Omisirge from community.
know could opportunity or investment a partnership, a could We and we education, momentum more. is resources have the also where though, do educationally more much signals or to apply in more more additional from and significant that market. quickly. strategic that the launch the acknowledge, We market research so and be area we doing is we ultimately could to the if post-approval can market, I more sensitive we centers the capturing successful want transplant onboard secure resources it of could drive The interest an this be. more more this will pre- Omisirge
start our some progress runway press note extending enables gross early received while the $XX.X launch of Omisirge securities. This to want additional also a of into we jump from our offering that in Company’s release, we funding position. public noted us financial I cash In million recently stabilizing XXXX. proceeds the to
on reduced Highbridge’s cut our also convertible combination by XXXX We Management from Highbridge half has installment Through $XX.X redemptions this a $XX of as debt loan. term loan million obligation of these our secured of the been senior million and December to actions, outstanding in share balance through Capital XXth. principal payments May
terms our of can efforts we pursuing potential of actively resource partners, In corporate also element commercial more discussions our robustly. that partnerships and including help strategic two-pronged second the pharmaceutical U.S. with are with global companies strategy, biotech and
who help We’re are making ongoing there partner, of banking has LLC, well as significant progress Company conversations, and & the post active with We’ve and approval. been supporting interest had here the process. Moelis
XXXX. debt right raising into So promised equity, tightening our we’ve belt focused we extending company, on moves, and the are. expenses, to summarize, reducing more we cash a we be believe that runway We streamlined our made and and would
confident more with We from we’re great on maximize and are seeing access that transplant centers. value And seeing support shareholders. interest to the through quickly from we’re Omisirge we for partnership, capitalize interest payers and for launching and patients can their coverage strategic the
‘XX over I to call will now to Shai financial Shai, results. over you. turn review our the to QX
